OPRX

OptimizeRx (OPRX)

OptimizeRx Corporation

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:OPRX

<< 前へ 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2019/06/05	21 : 50	GlobeNewswire Inc.	OptimizeRx Announces Pricing of Public Offering of Common Stock	NASDAQ:OPRX	OptimizeRx Corporation
2019/06/05	05 : 12	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:OPRX	OptimizeRx Corporation
2019/06/05	05 : 01	GlobeNewswire Inc.	OptimizeRx Announces Proposed Public Offering of Common Stock	NASDAQ:OPRX	OptimizeRx Corporation
2019/06/01	01 : 52	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:OPRX	OptimizeRx Corporation
2019/05/31	23 : 30	GlobeNewswire Inc.	OptimizeRx to Participate at Investor Conferences in June	NASDAQ:OPRX	OptimizeRx Corporation
2019/05/23	06 : 04	Edgar (US Regulatory)	Amended Statement of Changes in Beneficial Ownership (4/a)	NASDAQ:OPRX	OptimizeRx Corporation
2019/05/18	05 : 06	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPRX	OptimizeRx Corporation
2019/05/14	05 : 43	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPRX	OptimizeRx Corporation
2019/05/13	21 : 46	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPRX	OptimizeRx Corporation
2019/05/11	05 : 19	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:OPRX	OptimizeRx Corporation
2019/05/09	21 : 46	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:OPRX	OptimizeRx Corporation
2019/05/09	05 : 08	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:OPRX	OptimizeRx Corporation
2019/05/09	05 : 01	GlobeNewswire Inc.	OptimizeRx Reports First Quarter 2019 Results; Total Revenue Up 27% to $5.2 Million, Driving Non-GAAP Net Income up 130% to $...	NASDAQ:OPRX	OptimizeRx Corporation
2019/05/04	06 : 13	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPRX	OptimizeRx Corporation
2019/05/04	06 : 09	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPRX	OptimizeRx Corporation
2019/05/04	06 : 08	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:OPRX	OptimizeRx Corporation
2019/05/04	06 : 07	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:OPRX	OptimizeRx Corporation
2019/04/30	23 : 21	PR Newswire (US)	EVERSANA and OptimizeRx Partner to Deliver High Tech and High Touch Pharmaceutical Services	NASDAQ:OPRX	OptimizeRx Corporation
2019/04/29	22 : 01	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:OPRX	OptimizeRx Corporation
2019/04/29	21 : 31	GlobeNewswire Inc.	OptimizeRx Strengthens Executive Leadership with Appointment of Chief Commercial Officer	NASDAQ:OPRX	OptimizeRx Corporation
2019/04/27	05 : 28	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:OPRX	OptimizeRx Corporation
2019/04/27	00 : 30	GlobeNewswire Inc.	OptimizeRx Sets First Quarter 2019 Conference Call for Wednesday, May 8, 2019 at 4:30 p.m. ET	NASDAQ:OPRX	OptimizeRx Corporation
2019/04/24	01 : 57	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:OPRX	OptimizeRx Corporation
2019/04/23	21 : 31	GlobeNewswire Inc.	OptimizeRx to Present at Investor Conferences in May	NASDAQ:OPRX	OptimizeRx Corporation
2019/04/08	22 : 59	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:OPRX	OptimizeRx Corporation
2019/04/08	21 : 31	GlobeNewswire Inc.	OptimizeRx Expands Investment in Hospitals and Health Systems with Latest Tech and Personnel Adds	NASDAQ:OPRX	OptimizeRx Corporation
2019/03/30	05 : 29	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPRX	OptimizeRx Corporation
2019/03/30	05 : 26	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPRX	OptimizeRx Corporation
2019/03/30	05 : 26	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPRX	OptimizeRx Corporation
2019/03/30	05 : 23	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPRX	OptimizeRx Corporation